Abstract
Addiction involves complex physiological processes, and is characterised not only by broad phenotypic and behavioural traits, but also by ongoing molecular and cellular adaptations. In recent years, increasingly effective and novel techniques have been developed to unravel the molecular implications of addiction. Increasing evidence has supported a contribution of the nuclear transcription factor CREB in the development of addiction, both in contribution to phenotype and expression in brain regions critical to various aspects of drug-seeking behaviour and drug reward. Abstracting from this, models have exploited these data by removing the CREB gene from the developing or developed mouse, to crucially determine its impact upon addiction-related processes. More recent models, however, hold greater promise in unveiling the contribution of CREB to disorders such as addiction.
Keywords: CREB, conditional knockout, addiction, cAMP response element binding protein, behavior
Current Neuropharmacology
Title: The Nuclear Transcription Factor CREB: Involvement in Addiction, Deletion Models and Looking Forward
Volume: 5 Issue: 3
Author(s): Cameron S. McPherson and Andrew J. Lawrence
Affiliation:
Keywords: CREB, conditional knockout, addiction, cAMP response element binding protein, behavior
Abstract: Addiction involves complex physiological processes, and is characterised not only by broad phenotypic and behavioural traits, but also by ongoing molecular and cellular adaptations. In recent years, increasingly effective and novel techniques have been developed to unravel the molecular implications of addiction. Increasing evidence has supported a contribution of the nuclear transcription factor CREB in the development of addiction, both in contribution to phenotype and expression in brain regions critical to various aspects of drug-seeking behaviour and drug reward. Abstracting from this, models have exploited these data by removing the CREB gene from the developing or developed mouse, to crucially determine its impact upon addiction-related processes. More recent models, however, hold greater promise in unveiling the contribution of CREB to disorders such as addiction.
Export Options
About this article
Cite this article as:
McPherson S. Cameron and Lawrence J. Andrew, The Nuclear Transcription Factor CREB: Involvement in Addiction, Deletion Models and Looking Forward, Current Neuropharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157015907781695937
DOI https://dx.doi.org/10.2174/157015907781695937 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
New Insights into the Biology of 1-Antitrypsin and its Role in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets Articulating A Rights-Based Approach to HIV Treatment and Prevention Interventions
Current HIV Research Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Computerized Methods in the Assessment and Prediction of Dementia
Current Alzheimer Research The Ayurvedic Bhasma: The Ancient Science of Nanomedicine
Recent Patents on Nanomedicine Ghrelin in Central Neurons
Current Neuropharmacology Towards a Dynamic Exploration of Vision, Cognition and Emotion in Alcohol-Use Disorders
Current Neuropharmacology Detecting Gene-Gene Interactions Associated with Multiple Complex Traits with U-Statistics
Current Genomics Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Fullerene-like Nanoparticles of Titanium Disulfide
Current Nanoscience Cofilin Rod Formation in Neurons Impairs Neuronal Structure and Function
CNS & Neurological Disorders - Drug Targets Pathophysiological Features of Obesity and its Impact on Cognition: Exercise Training as a Non-Pharmacological Approach
Current Pharmaceutical Design Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Current Pharmaceutical Design Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery